ArticleIn vitro models2022
A culture model for the assessment of phenylalanine neurotoxicity in phenylketonuria.
Article in In vitro models, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Quantitative Ultrasound for the Assessment of Bone Quality in Hyperphenylalaninemia/Phenylketonuria Patients: Vitamin D Supplementation Versus No Supplementation.Metabolites · 2025Article
- Transcriptome Profiling of Phenylalanine-Treated Human Neuronal Model: Spotlight on Neurite Impairment and Synaptic Connectivity.International journal of molecular sciences · 2024Article
- Compromised white matter is related to lower cognitive performance in adults with phenylketonuria.Brain communications · 2023Article
- Serum glial fibrillary acidic protein and neurofilament light chain in patients with early treated phenylketonuria.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Phenylketonuria (PKU) is caused by a specific mutation of the phenylalanine hydroxylase (PAH) gene. The deficiency of PAH results in high phenylalanine levels (Phe), low tyrosine levels (Tyr), and reduced catecholamine neurotransmitters. The majority of PKU patients, if untreated, develop severe mental retardation. The specific contribution of high Phe and low Tyr levels in mental retardation is largely unknown. In this study, we used organic hippocampal slice cultures in an optimized medium as an adequate culture model to decipher the precise role of high Phe and low Tyr levels on synaptic and glial integrity in PKU. The hippocampus is closely related to learning and memory and reduced catecholamine neurotransmitter levels can be neglected since these neurotransmitters do not derive from the hippocampus. Cultures exposed to physiological concentrations of Phe were compared with cultures exposed to doses of Phe/Tyr, as in the cerebral fluid of PKU patients. Methods: Using capillary western blot analysis and immunohistochemistry, followed by quantitative image analysis, we tested the expression of various pre- and postsynaptic proteins (PSD95, synaptopodin, SNAP25, synaptophysin), glial cell markers (GFAP, Iba1, P2Y12, CD68, C3b), and the morphology of glial cells. Results: We found a downregulation of the postsynaptic protein PSD95 and the presynaptic protein SNAP25 in the presence of high/low Phe/Tyr levels after 3 weeks, which, then however, recovered after 6 weeks in culture. Furthermore, no change in the expression pattern of glial proteins was observed. Conclusion: Our results show that high Phe levels/low Tyr levels alone are unlikely to substantially contribute to mental retardation in PKU. The direct neurotoxic potency of high Phe/low Tyr concentrations is almost negligible since the effects are transient. The transient character in the presence of unchanged levels of high Phe/low Tyr points to a role of reduced catecholamine derivate neurotransmitters, rather than of high Phe/low Tyr levels in PKU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.